Создание иммуногена на основе белка p17 ВИЧ-1 субтипа A
Диссертация
Разработана эффективная схема иммунизации рекомбинантным белком р17 ВИЧ-1 субтипа, А российского изолята (однократное парентеральное праймирование белком р17 совместно с ИЛ-lß-H последующие двукратное интраназальное бустирование р 17+ИЛ-1 ?) для индукции высоких уровней IgA к р17 на всех слизистых оболочках и для индукции высоких уровней IgG в системном кровотоке. Полученная схема вакцинации… Читать ещё >
Список литературы
- Колобов А. А., Колодкин Н. И., Золотарев Ю. А., Тафил С., Наволоцкая Е. В. Взаимодействие синтетического иммуномодулирующего дипептида бестима с макрофагами и тимоцитами мыши // Биоорг. Хим. 2008. — Т.34. -№ 1. — С. 43−49.
- Лобзин Ю.В., А.Л. Позняк, A.C. Симбирцев, А.Ю. Котов, A.A. Колобов, В. М. Мудрицкий. Эффективность применения иммунопрепарата Бестим при острой нейроинфекции хламидийного генеза // Цитокины и воспаление. 2004. — № 4. — С. 2426.
- Петров A.B., Пигарева Н. В., Котов А. Ю., Колобов A.A., Симбирцев A.C. Изучение влияния Бестима (SCV-07) на дифференцировку Т-лимфоцитов у мышей // Цитокины и воспаление. 2007. — Т.6. — № 3. — С. 2731.
- Пигарева Н.В., Сахарова И. Я., Васильева Г. Ю. Бестим в комплексной терапии туберкулеза легких. Под ред. Ю. Н. Левашева и А. С. Симбирцева // -СПб.: «Борей-Арт», 2007. -68 С.
- Пигарева Н.В., Симбирцев A.C., Колобов A.A., Калинина Н. М., Кауров O.A., Кетлинский С. А. Изучение иммуномодулирующей активности нового пептидного соединения бестима // Иммунология. 2000. — № 1. — С. 33−35.
- Симбирцев A.C. Биология семейства интерлейкина1 человека // Иммунология. 1998. — № 3. — С. 9−17.
- Aimanianda V, Haensler J, Lacroix-Desmazes S, Kaveri SV, Bayry J. Novel cellular and molecular mechanisms of induction of iMMune responses by aluminum adjuvants // Trends Pharmacol Sei. 2009. — V. 30(6). — P. 287−95.
- Albini A, Ferrini S, Benelli R, Sforzini S, Giunciuglio D, Aluigi MG, Proudfoot AE, Alouani S, Wells TN, Mariani G, Rabin RL, Farber JM, Noonan DM. HIV-1 Tat protein mimicry of chemokines // Proc Natl Acad Sei U S A. -1998.-V. 95.-P. 13 153−13 158.
- Alcami A, Ghazal P, Yewdell JW. Viruses in control of the iMMune system. Workshop on molecular mechanisms of iMMune modulation: lessons from viruses //EMBO. 2002. — V. 3. — P. 927−932.
- Alcami A. Viral mimicry of cytokines, chemokines and their receptors // Nat Rev iMMunol. 2003. — V. 3. — P. 36−50.
- Alfano M, Poli G. Cytokine and chemokine based control of HIV infection and replication // Curr Pharm Des. 2001. — V. 7. — P. 993−1013.
- Almeida M, Cordero M, Almeida J, Orfao A. Different subsets of peripheral blood dendritic cells show distinct phenotypic and functional abnormalities in HIV-1 infection//AIDS. -2005. -V. 19. P. 261−271.
- Anthony DD, Yonkers NL, Post AB, Asaad R, Heinzel FP, Lederman MM, Lehmann PV, Valdez H. Selective impairments in dendritic cell-associated function distinguish hepatitis C virus and HIV infection // J IMMunol. 2004. — V. 40.-P. 738−746.
- Aoki Y., Tosato G. Neoplastic conditions in the context of HIV-1 infection // Curr. HIV. Res. 2004. — V. 2. — P. 343−349.
- Ayna A., Amelia Still, and Eric Barklis. Analysis of Human IMMunodeficiency Virus Type 1 Matrix Binding to Membranes and Nucleic Acids // Journal of Virology. 2009. — V. 83(23). — P. 12 196−12 203.
- Baneyx F. Recombinant protein expression in Escherichia coli // Curr Opin Biotechnol. 1999. — V. 10. — P. 411−421.
- Batista-Duharte A, Lindblad EB, Oviedo-Orta E. Progress in understanding adjuvant iMMunotoxicity mechanisms // Toxicol Lett. 2011. — V. 203(2). — P. 97 105.
- Battle-Miller K, Eby CA, Landay AL, Cohen MH, Sha BE, Baum LL. Antibody-dependent cell-mediated cytotoxicity in cervical lavage fluids of human iMMunodeficiency virus type 1-infected women // J Infect Dis. 2002. — V. 185. -P. 439−447.
- Beckwith J. The operon: An historical account // F.C. Neidhardt (Ed.), Escherichia Coli and Salmonella Typhimurium: Cellular and Molecular Biology Biology, American Society for Microbiology, Washington, D.C. 1987. — P. 1439−1452.
- Belyakov IM, Ahlers JD. Mucosal IiviMunity and HIV-1 Infection: Applications for Mucosal AIDS Vaccine Development // Curr Top Microbiol iMMunol. 2011. — Epub ahead of print.
- Belyakov IM, Ahlers JD. Simultaneous Approach Using Systemic, Mucosal and Transcutaneous Routes of iMMunization For Development of Protective HIV-1 Vaccines // Curr Med Chem. -2011.- Epub ahead of print.
- Belyakov IM, Berzofsky JA. iMMunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccines // iMMunity. 2004. — V. 20. — P. 247−253.
- Bhattacharya J, Repik A, Clapham P. Gag regulates association of HIV-1 envelope with detergent-resistant membranes // J. Virol. 2006. — V. 80. — P. 5292−5300.
- Billiau A, Matthys P. Modes of action of Freund’s adjuvants in experimental models of autoiMMune diseases // J Leukoc Biol. 2001. — V. 70(6). — P. 849−60.
- Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP. Natural killer cells in antiviral defense: function and regulation by innate cytokines // Annu Rev iMMunol. 1999. — V. 17. — P. 189−220.
- Blank SE, Leslie GA, Clem W. Antibody affinity and valence in viral neutralization // J IMMunol. 1972. — V. 108. — P. 665−73.
- Boraschi D, Tagliabue A. Interleukin-1 and interleukin-1 fragments as vaccine adjuvants // Methods. 1999. — V. 19(1). — P. 108−13.
- Boucher CA, Krone WJ, Goudsmit J, Meloen RH, Naylor PH, Goldstein AL, Sun DK, Sarin PS. iMMune response and epitope mapping of a candidate HIV-1 pl7 vaccine HGP30 // J Clin Lab Anal. 1990. — V. 4(1). — P. 43−7.
- Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding // Anal. Biochem. 1976. — V. 72. — P. 248−254.
- Briggs JA, Krausslich HG. The Molecular Architecture of HIV // J Mol Biol. -2011.-V. 410(4).-P. 491−500.
- Brinkmann U, Mattes RE, Buckel P. High-level expression of recombinant genes in Escherichia coli is dependent on the availability of the dnaY gene product // Gene. 1989. — V. 85. — P. 109−114.
- Bukrinskaya A, Vorkunova G, Burstein M, Stevenson M. Intracellularly cleaved HIV-1 matrix protein is packaged into virions // Doklady Biol. Sci. (Mosc.). 2006. — V. 404. — P. 249−252.
- Bukrinskaya A, Vorkunova G, Tentsov Y. HIV-1 matrix protein pi7 resides in cell nuclei in association with genomic RNA // AIDS Res. Hum. Retroviruses. -1992.-V. 8.-P. 1795−1801.
- Bukrinskaya A. The activity of the protease of HIV-1 is initiated at the membrane of infected cells before the release of viral proteins and is required for release to occur with maximum efficiency // Virus Res. 2007. — V. 124. — P. 111.
- Bukrinsky M. A hard way to the nucleus // Mol. Med. 2004. — V. 10. — P. 1−6.
- Burnette B, Kahn R, Glover CJ, Felsted RL. Bacterial expression, purification, and in vitro N-myristoylation of HIV-1 pl7gag // Protein Expr Purif.- 1992.-V. 3,-P. 395−402.
- Caputo A, Gavioli R, Bellino S, Longo O, Tripiciano A, Francavilla V, Sgadari C, Paniccia G, Titti F, Cafaro A, Ferrantelli F, Monini P, Ensoli F, Ensoli
- B. HIV-1 Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development // Int Rev iMMunol. 2009. — V. 28(5). — P. 285 334.
- Cella M, Jarrossay D, Facchetti F, Alebardi O, Nakajima H, Lanzavecchia A, Colonna M. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon // Nat Med. 1999. — V. 5. — P. 919— 923.
- Cerutti A, Chen K, Chorny A. iMMunoglobulin responses at the mucosal interface // Annu Rev IMMunol. 2011. — V. 29. — P. 273−93.
- Cerutti A. The regulation of IgA class switching // Nat Rev IMMunol. -2008.-V. 8(6).-P. 421−34.
- Chargelegue D, C M O’Toole, and B T Colvin Clin. A longitudinal study of the IgG antibody response to HIV-1 pi7 gag protein in HIV-1+ patients with haemophilia: titre and avidity // Exp IMMunol. 1993. — V. 93(3). — P. 331−336.
- Chargelegue D, Stanley CM, O’Toole CM, Colvin BT, Steward MW. The affinity of IgG antibodies to gag p24 and pi7 in HIV-1-infected patients correlates with disease progression // Clin Exp IMMunol. 1995. — V. 99(2). — P. 175−81.
- Cheng C, Shuman S. DNA strand transfer catalyzed by vaccinia topoisomerase: ligation of DNAs containing a 3' mononucleotide overhang // Nucleic Acids Res. -2000. -V. 28. P. 1893−1898.
- Christopher P. Jones, Siddhartha A. K. Datta, Alan Rein, Ioulia Rouzina, and Karin Musier-Forsyth. Matrix Domain Modulates HIV-1 Gag’s Nucleic Acid Chaperone Activity via Inositol Phosphate Binding // Journal of Virology. 2011. -V. 85(4).-P. 1594−1603.
- Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells // Science. 1995. — V. 270. — P. 1811−1815.
- Colonna M, Krug A, Cella M. Interferon-producing cells: on the front line in iMMune responses against pathogens // Curr Opin iMMunol. 2002. — V. 14. — P. 373−379.
- Conte MR, Matthews S. Retroviral matrix proteins: A structural perspective. //Virology. 1998.-V. 246.-P. 191−198.
- Cosson P. Direct contact between the envelope and matrix protein of HIV-1 //EMBO J. 1996.-V. 15.-P. 5783−5788.
- Dalton AK, Murray PS, Murray D, Vogt VM. Biochemical characterization of Rous sarcoma virus MA protein interaction with membranes // J. Virol. 2005. -V. 79.-P. 6227−6238.
- Das S, Dixon JE, Cho W. Membrane-binding and activation mechanism of PTEN // Proc Natl Acad Sci USA. 2003. — V. 100. — P. 7491−7496.
- Davis M, Aiken C. Role of the MA protein in HIV-1 core function // Materials of Retrovirus Meeting Cold Spring Harbor, New York. 2005. — P. 2429.
- Davis M, Jiang J, Zhou J, Freed E, Aiken C. A mutation in the HIV-1 Gag protein destabilizes the interaction of the envelope protein subunits gpl20 and gp41 //J. Virol.-2006.-V. 80.-P. 2405−2417.
- De Francesco MA, Poiesi C, Ricotta D, Manca N. HIV pi7 reverses the anti-inflaMMatory activity of IL-4 on IL-15 stimulated monocytes and modulates their ability to secrete MIP-1 alpha // Virus Res. 2006. — V. 118. — P. 170−177.
- Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity // BMJ. 2009. — V. 338. — P. a3172.
- Dieli F, Asherson GL, Sireci G, Bonnano CT, Caccamo N, Salerno A. Interleukin 4 suppresses primary interferon gaMMa response by T cells iMMunized in vivo and cultured in vitro with interleukin 2 // Cytokine. 2003. — V. 120. — P. 294−299.
- DiMMock Nigel J. The complex antigenicity of a small external region of the C-terminal tail of the HIV-1 gp41 envelope protein: a lesson in epitope analysis // Rev. Med. Virol. -2005. -V. 15.-P. 365−381.
- Dinarello CA. iMMunological and inflaMMatory functions of the interleukin-1 family // Annu Rev iMMunol. 2009. — V. 27. — P. 519−50.
- Ding L, Derdowski A, Wang J, Spearman P. Independent segregation of HIV-1 Gag protein complexes and lipid rafts // J. Virol. 2003. — V. 77. — P. 1916−1926.
- Dong X, Li H, Derdowski A, Ding L, Burnett A, Chen X, Peters TR, Dermody TS, Woodruff E, Wang JJ, Spearman P. AP-3 directs the intracellular trafficking of HIV-1 Gag and plays a key role in particle assembly // Cell. 2005. -V. 120.-P. 663−674.
- Donovan RM, Bush CE, Markowitz NP, Baxa DM, Saravolatz LD. Changes in viral load markers during AIDS-associated opportunistic diseases in human iMMunodeficiency virus-infected persons // J Infect Dis. — 1996. — V. 174. P. 401−403.
- Dorfman T, MaMMano F, Haseltine WA, Gottlinger HG. Role of the matrix protein in the virion association of the HIV-1 envelope glycoprotein // J. Virol. -1994.-V. 68.-P. 1689−1696.
- Eisenbarth SC, Colegio OR, O’Connor W, Sutterwala FS, Flavell RA. Crucial role for the Nalp3 inflaMMasome in the iMMunostimulatory properties of aluminium adjuvants // Nature. 2008. — V. 453(7198). — P. 1122−6.
- Embretson J, Zupancic M, Ribas JL, Burke A, Racz P, Tenner-Racz K, Haase AT. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS // Nature. 1993. — V. 362. — P. 35 962.
- Ensoli B, Bellino S, Tripiciano A, Longo O, Francavilla V, Marcotullio S, Cafaro A, Picconi O, Paniccia G, Scoglio A, Arancio A, Ariola C, Ruiz Alvarez
- Facchetti F, Vermi W, Mason D, Colonna M. Interferon-producing cells: on the front line in iMMune responses against pathogens // Virchows Arch. 2003. -V. 443.-P. 703−717.
- Faham, S., Hileman, R.E., FroMM, J.R., Linhardt, R.J., Rees, D.C. Heparin structure and interactions with basic fibroblast growth factor // Science. 1996. -V. 271.-P. 1116−1120.
- Fauci AS, Frank MM, Johnson JS. The relationship between antibody affinity and efficiency of complement fixation // J iMMunol. 1970. — V. 105. — P. 215−20.
- Fiorentini S, Giagulli C, Caccuri F, Magiera AK, Caruso A. HIV-1 matrix protein pi7: a candidate antigen for therapeutic vaccines against AIDS // Pharmacol Ther. 2010. — V. 128(3). — P. 433−44.
- Fiorentini S, Marini E, Bozzo L, Trainini L, Saadoune L, Avolio M, Pontillo A, Bonfanti C, Sarmientos P, Caruso A. Preclinical studies on iMMunogenicity of the HIV-1 pl7-based synthetic peptide AT20-KLH // Biopolymer. 2004. — V. 76(4).-P. 334−43.
- Fiorentini S, Marini E, Caracciolo S, Caruso A. Functions of the HIV-1 matrix protein pl7 // New Microbiol. 2006. — V. 29. — P. 1−10.
- Forshey BM, von Swedler U, Sundquist WI, Aiken C. Formation of a HIV-1 core of optimal stability is crucial for virus replication // J. Virol. 2002. — V. 76. -P. 5667−5677.
- Forthal DN, Moog C. Fc receptor-mediated antiviral antibodies // Curr Opin HIV AIDS. 2009. — V. 4. — P. 388−393.
- Fountoulakis M, Juranville JF, Maris A, Ozmen L, Garotta G. One interferon gaMMa receptor binds one interferon gaMMa dimer // J Biol Chem. -1990. -V. 265. P. 19 758−19 767.
- Freed EO. HIV-1 gag proteins: diverse functions in the virus life cycle // Virology.- 1998,-V. 251.-P. 1−15.
- Frisch M, Biggar RJ, Engels EA, Goedert JJ- AIDS-Cancer Match Registry Study Group. Association of cancer with AIDS-related iMMunosuppression in adults //JAMA.- 2001. V. 285.-P. 1736−1745.
- Gallay P, Swingler S, Song J, Bushman F, Trono D. Nuclear import is governed by the phosphotyrosine-mediated binding of matrix to the core domain of integrase // Cell. 1995. — V. 83. — P. 569−576.
- Ganser B, Su L, Klishko V, Finch J, Sundquist W. Assembly and analysis of conical models for the HIV-1 core // Science. 1999. — V. 283. — P. 80−83.
- Giagulli C, Marsico S, Magiera AK, Bruno R, Caccuri F, Barone I, Fiorentini S, Ando S, Caruso A. Opposite effects of HIV-1 pl7 variants on PTEN activation and cell growth in B cells // PLoS One. 2011. — V. 6(3). — P el7831.
- Gibellini D, Re MC, Bassini A, Guidotti L, Catani L, La Placa M, Zauli G. HIV-1 gpl20 induces the activation of both c-fos and c-jun iMMediate-early genes in HEL megakaryocyte cells // Br J Haematol. 1999. — V. 104. — P. 81−86.
- Gillis S, Mochizuki DY, Conlon PJ, Hefeneider SH, Ramthun CA, Gillis AE, Frank MB, Henney CS, Watson JD. Molecular characterization of interleukin 2 // iMMunol Rev. 1982. — V. 63. — P. 167−209.
- Goletti D, Weissman D, Jackson RW, Graham NM, Vlahov D, Klein RS, Munsiff SS, Ortona L, Cauda R, Fauci AS. Effect of Mycobacterium tuberculosison HIV replication. Role of iMMune activation // J iMMunol. 1996. — V. 175. — P. 1271−1278.
- Gotch F, Hardy G, Imami N. Therapeutic vaccines in HIV. l infection // IMMunol Rev. 1999. — V. 170. — P. 173−82.
- Gould SJ, Booth AM, Hildreth JE. The Trojan exosome hypothesis // Proc Natl Acad Sci USA. 2003. — V. 100. — P. 10 592−10 597.
- Grandori C, Mac J, Siebelt F, Ayer DE, Eisenman RN. Myc-Max heterodimers activate a DEAD box gene and interact with multiple E box-related sites in vivo // EMBO J. 1996. — V. 15(16). — P. 4344−57.
- Grossman TH, Kawasaki ES, Punreddy SR, Osburne MS Spontaneous cAMP-dependent derepression of gene expression in stationary phase plays a role in recombinant expression instability // Gene. 1998. — V. 209. — P. 95−103.
- Gupta S, Arora K, Gupta A, Chaudhary VK. Gag-derived proteins of HIV-1 isolates from Indian patients: cloning, expression, and purification of pi 7 of B- and C-subtypes // Protein Expr Purif. 2001. — V. 21. — P. 378−385.
- Guy B. The perfect mix: recent progress in adjuvant research // Nat Rev Microbiol. 2007. — V. 5(7). — P. 505−17.
- Hannig G, Makrides SC. Strategies for optimizing heterologous protein expression in Escherichia coli // Trends in Biotechnology. 1998. — V. 16. — P. 54−60.
- He R, Leeson A, Andonov A, Li Y, Bastien N, Cao J, Osiowy C, Dobie F, Cutts T, Ballantine M, Li X. Activation of AP-1 signal transduction pathway by SARS Coronavirus nucleocapsid protein // Biochem Biophys Res CoMMun. -2003.-V. 311.-P. 870−876.
- Herbein G, Coaquette A, Perez-Bercoff D, Pacino G. Macrophage activation and HIV infection: can the Trojan horse turn into a fortress? // Curr Mol Med. -2002.-V. 2.-P. 723−738.
- Hermuda-Matsumoto L, Resh MD. HIV-1 protease triggers a myristoyl switch that modulates membrane binding of Pr55 Gag and pl7 MA // J. Virol. -1999.-V. 73.-P. 1902−1908.
- Herrick D, Parker R, Jacobson A. Identification and comparison of stable and unstable mRNAs in Saccharomyces cerevisiae // Mol Cell Biol. 1990. — V. 10.-P. 2269−2284.
- Hill WI, Worthylake CP, Bancroft D, Christensen DP, Sundquist AM. Crystal structure of the trimeric HIV-1 matrix protein: implication for membrane association and assembly // Proc. Natl. Acad. Sei. U.S.A. 1996. — V. 93. — P. 3099−30 104.
- Ho WZ, Cherukrui R, Douglas SD. The macrophage and HIV-1 // iMMunol Ser. 1994. — V. 60. — P. 569−587.
- Holloway G, Coulson BS. Rotavirus activates JNK and p38 signaling pathways in intestinal cells, leading to AP-1 -driven transcriptional responses and enhanced virus replication // J Virol. 2006. — V. 80. — P. 10 624−10 633.
- Hosmalin A, Lebon P. Type I interferon production in HIV-infected patients // J Leukoc Biol. 2006. — V. 80. — P. 984−993.
- Huber RE, Kurz G, Wallenfels K. A quantitation of the factors which affect the hydrolase and transgalactosylase activities of beta-galactosidase (E. coli) on lactose // Biochemistry. 1976. -V. 15. — P. 1994−2001.
- Inada T, Kimata K, Aiba H. Mechanism responsible for glucose-lactose diauxie in Escherichia coli: challenge to the cAMP model // Genes Cells. 1996. -V. 1.-P. 293−301.
- Ishikawa S, Hashinaka K, Hashida S, Oka S, Ishikawa E. Sensitive enzyme iMMunoassay of antibodies to HIV-1 pl7 antigen using indirectly iMMobilized recombinant pl7 for diagnosis of HIV-1 infection // J Clin Lab Anal. 1998. — V. 12.-P. 343−350.
- Jana S, Deb JK. Strategies for efficient production of heterologous proteins in Escherichia coli // Appl Microbiol Biotechnol. 2005. — V. 67. — P. 289−298.
- Jayasekera JP, Moseman EA, Carroll MC. Natural antibody and complement mediate neutralization of influenza virus in the absence of prior iMMunity // J Virol. -2007. V. 81.-P. 3487−3494.
- Kageyama S, Kurimura T. Disappearance of anti-pl7 correlates with successful isolation of human iMMunodeficiency virus and deterioration in clinical status Hint J STD AIDS.- 1990.-V. 1(2).-P. 129−31.
- Kane JF. Effects of rare codon clusters on high-level expression of heterologous proteins in Escherichia coli // Curr Opin Biotechnol. 1995. — V. 6. -P. 494−500.
- Kaushik R, Ratner L. Role of HIV-1 matrix phosphorylation in an early postentry step of virus replication // J. Virol. 2004. — V. 78. — P. 2319−2326.
- Kawai T, Akira S. The roles of TLRs, RLRs and NLRs in pathogen recognition // Int iMMunol. 2009. — V. 21(4). — P. 317−37.
- Kedzierska, K., Crowe, S.M., Turnville, S., and Cunningham, A.L. The influence of cytokines, chemokines and their receptors on HIV-1 replication in monocytes and macrophages // Rev Med Virol. 2003. — V. 13. — P. 39−56.
- Kido M, Yamanaka K, Mitani T, Niki H, Ogura T, Hiraga S. RNase E polypeptides lacking a carboxyl-terminal half suppress a mukB mutation in Escherichia coli // J Bacteriol. 1996. — V. 178. — P. 3917 -3925.
- Kiernan R, Ono A, Englund G, Freed E. Role of matrix in an early postentry step in the human iMMunodeficiency virus type 1 life cycle // J. Virol. 1998. — V. 72.-P. 4116−4126.
- Kieser A, Kilger E, Gires O, Ueffmg M, Kolch W, HaMMerschmidt W. Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade // EMBO J. 1997. — V. 16. — P. 6478−6485.
- Kimata K, Takahashi H, Inada T, Postma P, Aiba H. cAMP receptor proteincAMP plays a crucial role in glucose-lactose diauxie by activating the major glucose transporter gene in Escherichia coli // Proc Natl Acad Sei USA.- 1997. -V. 94.-P. 12 914−12 919.
- Kinter AL, Poli G, Fox L, Hardy E, Fauci AS. HIV replication in Unstimulated peripheral blood mononuclear cells is driven in an autocrine/paracrine manner by endogenous cytokines // J iMMunol. 1995. — V. 154. — P. 2448−2459.
- Kleber-Janke T, Becker WM. Use of modified BL21(DE3) Escherichia coli cells for high-level expression of recombinant peanut allergens affected by poor codon usage // Protein Expr Purif. 2000. — V. 19. — P. 419−424.
- Kolobov A.A., Simbirtsev A.S. Bestim is an unique regulator of iMMunity // New Information technologies in medicine, pharmacology and biology. Gurzuf, 2005.-P. 81−84.
- Kumar A, Manna SK, Dhawan S, Aggarwal BB. HIV-Tat protein activates c-Jun N-terminal kinase and activator protein-1 // J IMMunol. 1998. — V. 161. -P. 776−781.
- Kwon D, Fuller AC, Palma JP, Choi IH, Kim BS. Induction of chemokines in human astrocytes by Picornavirus infection requires activation of both AP-1 and NF-kappa B // Glia. 2004. — V. 45. — P. 287−296.
- LaeMMli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4 // Nature. 1970. — V. 227. — P. 680−685.
- Lai SK, Hida K, Shukair S, et al. Human iMMunodeficiency virus type 1 is trapped by acidic but not by neutralized human cervicovaginal mucus // J Virol. -2009. V. 83. — P. 11 196−11 200.
- Leslie NR, Batty IH, Maccario H, Davidson L, Downes CP. Understanding PTEN regulation: PIP2, polarity and protein stability // Oncogene. 2008. — V. 27.- P. 5464−5476.
- Li S., Luisa Bozzo, Zhibin Wu, Wuyuan Lu, Fabio Romerio. The HIV-1 matrix protein pi7 activates the transcription factors c-Myc and CREB in human B cells // New Microbiologica. 2010. — V. 33. — P. 13−24.
- Lopez PJ, Marchand I, Joyce SA, Dreyfus M. The C-terminal half of RNase E, which organizes the Escherichia coli degradosome, participates in mRNA degradation but not rRNA processing in vivo // Mol Microbiol. 1999. — V. 33. -P. 188−199.
- Lore K, Sonnerborg A, Brostrom C, Goh LE, Perrin L, McDade H, Stellbrink HJ, Gazzard B, Weber R, Napolitano LA, van Kooyk Y, Andersson J.
- Accumulation of DC-SIGN+CD40+ dendritic cells with reduced CD80 and CD86 expression in lymphoid tissue during acute HIV-1 infection // AIDS. 2002. — V. 16.-P. 683−692.
- Marcu KB, Bossone SA, Patel AJ. Myc function and regulation // Annu Rev Biochem. 1992. — V. 61. — P. 809−60.
- Martinelli E, Cicala C, Van Ryk D, Goode DJ, Macleod K, Arthos J, Fauci AS. HIV-1 gpl20 inhibits TLR9-mediated activation and IFN-{alpha} secretion in plasmacytoid dendritic cells // Proc Natl Acad Sci USA.- 2007. V. 104. — P. 3396−3401.
- Massiah MA, Starich MR, Paschall C, SuMMers MF, Christensen AM, Sundquist WI. Three-dimensional structure of the human iMMunodeficiency virus type 1 matrix protein // Journal of Molecular Biology. 1994. — V. 244, N. 2. — P. 198−223.
- McKee AS, Munks MW, Marrack P. How do adjuvants work? Important considerations for new generation adjuvants // iMMunity. 2007. — V. 27(5). — P. 687−90.
- Meadow ND, Fox DK, Roseman S. The bacterial phosphoenolpyruvate: glycose phosphotransferase system // Annu Rev Biochem. 1990. — V. 59. — P. 497−542.
- Mehta SU, Rupprecht KR, Hunt JC, Kramer DE, McRae BJ, Allen RG, Dawson GJ, Devare SG. Prevalence of antibodies to the core protein PI7, a serological marker during HIV-1 infection // AIDS Res Hum Retroviruses. 1990. -V. 6(4).-P. 443−54.
- Meili R, Sasaki AT, Firtel RA. Rho Rocks PTEN // Nat Cell Biol. 2005. -V. 7.-P. 334−335.
- Menu P, Vince JE. The NLRP3 inflaMMasome in health and disease: the good, the bad and the ugly // Clin Exp iMMunol. 2011. — Epub ahead of print.
- Mestecky J, Russell MW, Elson CO. Perspectives on mucosal vaccines: is mucosal tolerance a barrier? // J iMMunoi. 2007. — V. 179(9). — P. 5633−8.
- Mosser DD, Caron AW, Bourget L, Meriin AB, Sherman MY, Morimoto RI, Massie B. The chaperone function of hsp70 is required for protection against stress-induced apoptosis // Mol Cell Biol. 2000. — V. 20. — P. 7146−7159.
- Murakami T, Ablan S, Nagashima K, Komano J, Miyauchi K, Matsuda Z, Freed E, Yamamoto N. Characterization of HIV-1 matrix mutants: effect on the early stage of infection // Meeting Retroviruses Cold Spring Harbor, New York, May 24−29.-2005.
- Murakami T, Freed EO. Genetic evidence for an interaction between HIV-1 matrix and alfa-helix 2 of the gp41 cytoplasmic tail // J. Virol. 2000. — V. 74. — P. 3548−3554.
- Muriaux D, Costes S, Nagashima K, Mirro J, Cho E, Lockett S, Rein A. Role of murine leukemia nucleocapsid protein in virus assembly // J. Virol. 2004. -V. 78.-P. 12 378−12 385.
- Murray PS, Li Z, Wang J, Tang CL, Honig B, Murray D. Retroviral matrix domains share electrostatic homology: models for membrane binding function throughout the viral life cycle // Structure. 2005. — V. 13(10). — P. 1521−31.
- Nakae S, Asano M, Horai R, Iwakura Y. Interleukin-1(3, but not interleukin-la, is required for T-cell-dependent antibody production // iMMunology. 2001. -V. 104.-P. 402−9.
- Nara PL, Garrity RR, Goudsmit J. Neutralization of HIV-1: a paradox of humoral proportions // FASEB J. 1991. — V. 5. — P. 2437−55.
- Nickel W. The mystery of nonclassical protein secretion: A current view on cargo proteins and potential export routes // Eur J Biochem. 2003. — V. 270. — P. 2109−2119.
- Nohria A, Rubin RH. Cytokines as potential vaccine adjuvants // Biotherapy. 1994. — V. 7(3−4).-P. 261−9.
- Olszewska W, Obeid E. Obeid and Michael W. Steward. Protection against Measles Virus-Induced Encephalitis by Anti-mimotope Antibodies: The Role of Antibody Affinity // Virology. 2000. — V. 272 (1). — P. 98−105.
- Ono A, Demirov D, Freed E. Relationship between HIV-1 Gag multimerization and membrane binding // J. Virol. 2000. — V. 74. — P. 51 425 150.
- Ono A, Freed E. Binding of HIV-1 Gag to membrane: role of the matrix amino terminus // J. Virol. 1999. — V. 73. — P. 4136−4144.
- Ono A, Freed E. Cell-type dependent targeting of HIV-1 assembly to the plasma membrane and the multivesicular body // J. Virol. 2004. — V. 78. — P. 1552−1563.
- Ono A, Waheed AA, Joshi A, Freed E. Association of HIV-1 Gag with membrane does not require highly basic sequences in the nucleocapsid: use of a novel Gag multimerization assay // J. Virol. 2005. — V. 79. — P. 14 131−14 140.
- Osborn L, Kunkel S, Nabel GJ. Tumor necrosis factor alpha and interleukin 1 stimulate the human iMMunodeficiency virus enhancer by activation of the nuclear factor kappa B // Proc Natl Acad Sci USA.- 1989. V. 86. — P. 23 362 340.
- Ota A, Bautista AN, Yadav ML, Ueda S. Anti-P30−52 monoclonal antibody cross-reacted to Env V3 and inhibited the viral multiplication of HIV-1-infected MT-4 cells // Hybridoma. 1999. — V. 18(2). — P. 139−47.
- Ota A, Liu X, Fujio H, Sakato N, Ueda S. Random expression of human iMMunodeficiency virus-1 (HIV-1) pi7 (epitopes) on the surface of the HIV-1-infected cell // Hybridoma. 1998. — V. 17(1). — P. 73−5.
- Ota A, Ueda S. Analysis of the anti-HIV-1 activity of an anti-pl7-derivative peptide (P30−52) monoclonal antibody // Hybridoma. 1999b. — V. 18(4). — P. 305−14.
- Ota A, Ueda S. Inhibitory mechanism of anti-P30−52 monoclonal antibody against human iMMunodeficiency virus type 1 (HIV-1) multiplication in infected MT-4 cells // Hybridoma. 1999a. — V. 18(3). — P. 235−41.
- Ott D, Coren L, Gagliardi T. Redundant roles for nucleocapsid and matrix protein RNA-binding sequences in HIV-1 assembly // J. Virol. — 2005. V. 79. — P. 13 839−13 847.
- Paillart J-C, Gottlinger H. Opposing effect of HIV-1 matrix mutations support the myristil switch model of Gag membrane targeting // J. Virol. 1999. -V. 73.-P. 2604−2612.
- Pantaleo G, Graziosi C, Demarest JF, Butini L, Montroni M, Fox CH, Orenstein JM, Kotler DP, Fauci AS. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of the disease // Nature. 1993. -V. 362.-P. 355−8.
- Papsidero L D, Sheu M, and Ruscetti F W. Human iMMunodeficiency virus type 1-neutralizing monoclonal antibodies which react with pi7 core protein: characterization and epitope mapping // J Virol. 1989. — V. 63(1). — P. 267−272.
- Poiesi Claudio, Maria A. De Francesco, Manuela Baronio, Nino Manca. HIV-1 pl7 binds heparan sulfate proteoglycans to activated CD4+ T cells // Virus Research. 2008. — V. 132. — P. 25−32.
- Poli G, Fauci AS. Cytokine modulation of HIV expression // Semin iMMunol. 1993. — V. 5. — P. 165−173.
- Porath J, Carlsson J, Olsson I, Belfrage G. Metal chelate affinity chromatography, a new approach to protein fractionation // Nature. 1975. — V. 258.-P. 598−599.
- Pulliam L, Gascon R, Stubblebine M, McGuire D, McGrath MS. Unique monocyte subset in patients with AIDS dementia // Lancet. 1997. — V. 349. — P. 692−695.
- Pulliam L, Sun B, Rempel H. Invasive chronic inflaMMatory monocyte phenotype in subjects with high HIV-1 viral load // J NeuroiMMunol. 2004. — V. 157.-P. 93−98.
- Reeder J, Hochsmann M, Rehmsmeier M, Voss B, Giegerich R. Beyond Mfold: recent advances in RNA bioinformatics // J Biotechnol. 2006. — V. 124. — P. 41−55.
- Resh MD. A myristoyl switch regulates membrane binding of HIV-1 Gag // Proc. Natl. Acad. Sci. U.S.A. 2004. — V. 101. — P. 417−418.
- Rexach M, Blobel G. Protein import into nuclei: association and dissociation reactions involving transport substrate, transport factors, and nucleoporins // Cell. 1995.-V. 83.-P. 683−692.
- Romani B, Engelbrecht S, Glashoff RH. Functions of Tat: the versatile protein of human iMMunodeficiency virus type 1 // J Gen Virol. 2010. — V. (Pt 1).-P. 1−12.
- Sadowska B, Barrueco R, Khalili K, Safak M. Regulation of human Polyomavirus JC virus gene transcription by AP-1 in glial cells // J Virol. 2003. -V. 77.-P. 665−672.
- Saier MH Jr, Crasnier M. Inducer exclusion and the regulation of sugar transport // Res Microbiol. 1996. — V. 147. — P. 482−489.
- Sanchez-Beato M, Sanchez-Aguilera A, Piris MA. Cell cycle deregulation in B-cell lymphomas//Blood.-2003.-V. 101.-P. 1220−1235.
- Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors // Proc Natl Acad Sei USA.- 1977. V. 74. — P. 5463−5467.
- Sarin PS, Sun DK, Thornton AH, Naylor PH, Goldstein AL. Neutralization of HTLV-III/LAV replication by antiserum to thymosin alpha 1 // Science. 1986. -V. 30, 232(4754).-P. 1135−1137.
- Scarlata S, Ehrlich LS, Carter CA. Membrane-induced alterations in HIV-1 Gag and matrix protein-protein interactions // J Mol Biol. 1998. — V. 277. — P. 161−169.
- Schmidt B, Scott I, Whitmore RG, Foster H, Fujimura S, Schmitz J, Levy JA. Low-level HIV infection of plasmacytoid dendritic cells: onset of cytopathic effects and cell death after PDC maturation // Virology. 2004. — V. 329. — P. 280−288.
- Scholz I, Arvidson B, Huseby D, Barklis E. Virus particle core defects caused by mutations in the HIV capsid N-terminal domain // J. Virol. 2005. — V. 79.-P. 1470−1479.
- Shacklett BL, Ferre AL. Mucosal iMMunity in HIV controllers: the right place at the right time // Curr Opin HIV AIDS. 2011 — V. 6(3). — P. 202−7.
- Shearer GM, Clerici M. Early T-helper cell defects in HIV infection // AIDS.-1991.-V. 5.-P. 245−53.
- Shim H, Dolde C, Lewis BC, Wu CS, Dang G, Jungmann RA, Dalla-Favera R, Dang CV. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth // Proc. Natl. Acad. Sci. USA. 1997. — V. 94. — P. 6658−6663.
- Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, Ho S, Antonenko S, Liu YJ. The nature of the principal type 1 interferon-producing cells in human blood // Science. 1999. — V. 284. — P. 1835−1837.
- Sinicco A, Biglino A, Sciandra M, Forno B, Pollono AM, Raiteri R, Gioannini P. Cytokine network and acute primary HIV-1 infection // AIDS. -1993.-V. 7.-P. 1167−1172.
- Sozzani S. Dendritic cell trafficking: more than just chemokines // Cytokine Growth Factor Rev.-2005.-V. 16.-P. 581−592.
- Spanjaard RA, van Duin J. Translation of the sequence AGG-AGG yields 50% ribosomal frameshift // Proc Natl Acad Sci USA.- 1988. V. 85. — P. 7967−7971.
- Spillmann, D. Heparan sulfate: anchor for viral intruders? // Biochimie. -2001.-V. 83.-P. 811−817.
- Staats HF, Nichols WG, Palker TJ. Mucosal iMMunity to HIV-1: systemic and vaginal antibody responses after intranasal iMMunization with the HIV-1 C4/V3 peptide T1SP10 MN (A) // J ImMuiioL 1996. — V. 157(1). — P. 462−72.
- Staruch MJ, Wood DD. The adjuventicity of interleukin 1 in vivo // J iMMunol. 1983. -V. 130. — P. 2191−2194.
- Steward MW, Stanley CM, Dimarchi R, Mulcahy G, Doel TR. High-affinity antibody induced by iMMunization with a synthetic peptide is associated with protection of cattle against foot-andmouth disease // iMMunology. 1991. — V. 72. -P. 99−103.
- Steward MW, Steensgaard J. Antibody affinity: thermodynamic aspects and biological significance // Boca Raton: CRC Press. 1983.
- Studier FW, Moffatt BA. Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes // J Mol Biol. 1986. — V. 189.-P. 113−130.
- Studier FW. Protein production by auto-induction in high density shaking cultures // Protein Expr Purif. 2005. — V. 41. — P. 207−234.
- Takeuchi O, Akira S. Pattern recognition receptors and inflaMMation // Cell. 2010. — V. 140(6). — P. 805−20.
- Tang C, Loeliger E, Luncsford P, Kinde I, Beckett D, SuMMers MF. Entropie switch regulates myristate exposure in the HIV-1 matrix protein // Proc. Natl. Acad. Sei. U.S.A. 2004. — V. 101. — P. 517−522.
- Thomas HI, Wilson S, O’Toole CM, Lister CM, Saeed AM, Watkins RP, Morgan-Capner P. Differential maturation of avidity of IgG antibodies to gp41, p24 and pi7 following infection with HIV-1 // Clin Exp IMMunol. 1996. — V. 103(2).-P. 185−91.
- Tomaras GD, Haynes BF. Strategies for eliciting HIV-1 inhibitory antibodies // Curr Opin HIV AIDS. 2010. — V. 5(5). — P. 421−7.
- Torres J, Pulido R. The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation // J Biol Chem. 2001. — V. 276. — P. 993−998.
- VanCott TC, Bethke FR, Polonis VR et al. Dissociation rate of antibody-gpl20 binding interactions is predictive of V3-mediated neutralization of HIV-1 // J iMMunol. 1994. -V. 153. — P. 449−59.
- Verli H, Calazans A, Brindeiro R, Tanuti A, Gulmaraes J. Molecular dynamics analysis of HIV-1 matrix protein: clarifying differences between crystallographic and solution structures // J. Mol. Graph. Model. 2007. — V. 26, N. l.-P. 62−68.
- Vicenzi E, Biswas P, Mengozzi M, Poli G. Role of pro-inflaMMatory cytokines and beta-chemokines in controlling HIV replication // J Leukoc Biol. -1997.-V. 62.-P. 3440.
- Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer // Nat Rev Cancer. 2002. — V. 2. — P. 489−501.
- Wahl SM, Greenwell-Wild T, Peng G, Ma G, Orenstein JM, Vazquez N. Viral and host cofactors facilitate HIV-1 replication in macrophages // J Leukoc Biol. 2003. — V. 74. — P. 726−735.
- Weinberg JB, Matthews TJ, Cullen BR, Malim MH. Productive human iMMunodeficiency virus type 1 (HIV-1) infection of nonproliferating human monocytes //J. Exp. Med. 1991. — V. 174. — P. 1477−1482.
- Wen YM, Duan SC, Howard CR, Frew AF, Steward MW. The affinity of anti-HBc antibodies in acute and chronic hepatitis B infection // Clin Exp iMMunol. 1990. -V. 79. — P. 83−86.
- White PC, Shore AM, Clement M, McLaren J, Soeiro I, Lam EW, Brennan P. Regulation of cyclin D2 and the cyclin D2 promoter by protein kinase A and CREB in lymphocytes // Oncogene. 2006. — V. 25. — P. 2170−2180.
- Wills JW, Craven RC. Form, function, and use of retroviral gag proteins // AIDS. 1991.-V. 5, N. 6.-P. 639−654.
- Xie J, Pan H, Yoo S, Gao SJ. Kaposi’s sarcoma-associated herpesvirus induction of AP-1 and interleukin 6 during primary infection mediated by multiple mitogen-activated protein kinase pathways // J Virol. 2005. — V. 79. — P. 1 502 715 037.
- Yu X, Yuan X, Matsuda Z, Lee TH, Essex M. The matrix protein of HIV-1 is required for incorporation of viral envelope protein into mature virions // J. Virol. 1992. — V. 66. — P. 4966−4971.
- Zinkernagel RM, Hengartner H. T-cell-mediated iMMunopathology versus direct cytolysis by virus: implication for HIV and AIDS // IMMunol Today. 1994. -V. 15.-P. 262−8.